Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

neogenomics inc. - NEO

NEO

Close Chg Chg %
13.22 -0.39 -2.95%

Closed Market

12.83

-0.39 (2.95%)

Volume: 1.98M

Last Updated:

Jan 15, 2026, 4:00 PM EDT

Trade Now

Company Overview: neogenomics inc. - NEO

NEO Key Data

Open

$13.19

 Day Range

12.81 - 13.29

52 Week Range

4.72 - 15.32

 Market Cap

$1.71B

Shares Outstanding

129.39M

 Public Float

123.12M

Beta

1.57

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.89

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.75M

  

NEO Performance

1 Week
 
 -2.51%
 
1 Month
 
 8.45%
 
3 Months
 
 27.66%
 
1 Year
 
 -9.71%
 
5 Years
 
 -75.69%
 

NEO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About neogenomics inc. - NEO

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

NEO At a Glance

NeoGenomics, Inc.
9490 NeoGenomics Way
Fort Myers, Florida 33912
Phone 1-239-768-0600 Revenue 660.57M
Industry Medical/Nursing Services Net Income -78,726,000.00
Sector Health Services 2024 Sales Growth 11.649%
Fiscal Year-end 12 / 2025 Employees 2,200
View SEC Filings

NEO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.16
Price to Book Ratio 2.34
Price to Cash Flow Ratio 297.21
Enterprise Value to EBITDA 2,706.354
Enterprise Value to Sales 3.491
Total Debt to Enterprise Value 0.263

NEO Efficiency

Revenue/Employee 300,257.273
Income Per Employee -35,784.545
Receivables Turnover 4.348
Total Asset Turnover 0.398

NEO Liquidity

Current Ratio 1.978
Quick Ratio 1.889
Cash Ratio 1.284

NEO Profitability

Gross Margin 38.854
Operating Margin -10.854
Pretax Margin -12.213
Net Margin -11.918
Return on Assets -4.744
Return on Equity -8.539
Return on Total Capital -5.222
Return on Invested Capital -5.522

NEO Capital Structure

Total Debt to Total Equity 67.085
Total Debt to Total Capital 40.15
Total Debt to Total Assets 36.955
Long-Term Debt to Equity 44.46
Long-Term Debt to Total Capital 26.609
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Neogenomics Inc. - NEO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
484.33M 509.73M 591.64M 660.57M
Sales Growth
+8.97% +5.24% +16.07% +11.65%
Cost of Goods Sold (COGS) incl D&A
304.76M 336.48M 382.17M 403.91M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
62.07M 79.20M 72.58M 72.55M
Depreciation
38.91M 45.15M 37.45M 39.10M
Amortization of Intangibles
23.16M 34.06M 35.13M 33.45M
COGS Growth
+9.24% +10.41% +13.58% +5.69%
Gross Income
179.57M 173.25M 209.47M 256.65M
Gross Income Growth
+8.52% -3.52% +20.91% +22.52%
Gross Profit Margin
+37.08% +33.99% +35.40% +38.85%
2021 2022 2023 2024 5-year trend
SG&A Expense
274.78M 323.88M 306.12M 328.35M
Research & Development
21.87M 30.33M 27.31M 31.16M
Other SG&A
252.91M 293.55M 278.81M 297.19M
SGA Growth
+54.48% +17.87% -5.48% +7.26%
Other Operating Expense
- - - -
-
Unusual Expense
15.64M 7.00M 11.09M 20.41M
EBIT after Unusual Expense
(110.85M) (157.62M) (107.74M) (92.11M)
Non Operating Income/Expense
100.86M (213.00K) 17.55M 18.05M
Non-Operating Interest Income
- - 16.90M 18.43M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
5.08M 1.51M 6.91M 6.62M
Interest Expense Growth
-27.60% -70.37% +358.63% -4.20%
Gross Interest Expense
5.08M 1.51M 6.91M 6.62M
Interest Capitalized
- - - -
-
Pretax Income
(15.07M) (159.34M) (97.10M) (80.67M)
Pretax Income Growth
-7.25% -957.00% +39.06% +16.91%
Pretax Margin
-3.11% -31.26% -16.41% -12.21%
Income Tax
(6.73M) (15.09M) (9.13M) (1.95M)
Income Tax - Current - Domestic
82.00K 135.00K 391.00K 546.00K
Income Tax - Current - Foreign
- - 17.00K 79.00K
-
Income Tax - Deferred - Domestic
666.00K (33.00K) 229.00K (331.00K)
Income Tax - Deferred - Foreign
(7.48M) (15.21M) (9.75M) (2.24M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(8.35M) (144.25M) (87.97M) (78.73M)
Minority Interest Expense
- - - -
-
Net Income
(8.35M) (144.25M) (87.97M) (78.73M)
Net Income Growth
-300.07% -1,628.17% +39.02% +10.51%
Net Margin Growth
-1.72% -28.30% -14.87% -11.92%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(8.35M) (144.25M) (87.97M) (78.73M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(8.35M) (144.25M) (87.97M) (78.73M)
EPS (Basic)
-0.0696 -1.1613 -0.7009 -0.6216
EPS (Basic) Growth
-281.25% -1,568.53% +39.65% +11.31%
Basic Shares Outstanding
119.96M 124.22M 125.50M 126.66M
EPS (Diluted)
-0.0696 -1.1613 -0.7009 -0.6216
EPS (Diluted) Growth
-286.60% -1,568.53% +39.65% +11.31%
Diluted Shares Outstanding
119.96M 124.22M 125.50M 126.66M
EBITDA
(33.14M) (71.42M) (24.07M) 852.00K
EBITDA Growth
-212.36% -115.51% +66.31% +103.54%
EBITDA Margin
-6.84% -14.01% -4.07% +0.13%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 13.50
Number of Ratings 14 Current Quarters Estimate 0.012
FY Report Date 03 / 2026 Current Year's Estimate 0.167
Last Quarter’s Earnings 0.04 Median PE on CY Estimate N/A
Year Ago Earnings 0.093 Next Fiscal Year Estimate 0.335
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 13 10
Mean Estimate 0.01 0.04 0.17 0.34
High Estimates 0.06 0.07 0.30 0.46
Low Estimate -0.04 -0.02 -0.01 0.12
Coefficient of Variance 270.12 72.67 50.61 28.89

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 7 7 8
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Neogenomics Inc. - NEO

Date Name Shares Transaction Value
Jan 7, 2026 John Patrick Kenny Director 5,893 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 John Patrick Kenny Director 4,171 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2025 Marjorie C. Green Director 22,964 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2025 Marjorie C. Green Director 16,019 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Warren Stone Pres & Chief Operating Officer 94,518 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Warren Stone Pres & Chief Operating Officer 52,687 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Anthony P. Zook Chief Executive Officer; Director 729,927 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Anthony P. Zook Chief Executive Officer; Director 421,496 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Gregory D. Aunan Chief Accounting Officer 31,163 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Melody Harris Chf Ops Off, Pres, Informatics 16,886 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2025 Melody Harris Chf Ops Off, Pres, Informatics 84,317 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Melody Harris Chf Ops Off, Pres, Informatics 109,755 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Feb 26, 2025 Melody Harris Chf Ops Off, Pres, Informatics 111,811 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2025 Gregory D. Aunan Chief Accounting Officer 18,971 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Christopher Michael Smith Chief Executive Officer 655,652 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2025 Jeffrey Scott Sherman Chief Financial Officer 126,476 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Jeffrey Scott Sherman Chief Financial Officer 214,900 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Jeffrey Scott Sherman Chief Financial Officer 137,064 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Feb 26, 2025 Jeffrey Scott Sherman Chief Financial Officer 141,271 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2025 Christopher Michael Smith Chief Executive Officer 114,826 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Neogenomics Inc. in the News